17587-95-0

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-N4-methylpyrimidine-4,5-diamine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to inhibit dihydrofolate reductase. This makes it a key component in the development of drugs targeting rapidly dividing cells, such as those found in cancer and certain infectious diseases.
Used in Antimalarial Drug Development:
In the field of antimalarial research, 2-chloro-N4-methylpyrimidine-4,5-diamine is utilized as a potential active ingredient. Its inhibitory effect on dihydrofolate reductase, an enzyme that malaria parasites also rely on for survival and reproduction, positions it as a candidate for new antimalarial drug formulations.
Used in Pesticide Formulation:
2-chloro-N4-methylpyrimidine-4,5-diamine is also used as a component in the development of agricultural chemicals, specifically pesticides. Its effectiveness in inhibiting essential enzymes in pests makes it a valuable tool in creating compounds that can control pest populations in farming.
Used as a Chemical Reagent:
In the broader context of chemical research and development, 2-chloro-N4-methylpyrimidine-4,5-diamine serves as an important reagent. Its unique structure and functional groups make it suitable for various chemical reactions and the synthesis of a wide range of organic compounds for different applications across industries.

InChI:InChI=1/C5H7ClN4/c1-8-4-3(7)2-9-5(6)10-4/h2H,7H2,1H3,(H,8,9,10)

Upstream product

• 89283-49-8 2-chloro-4-(methylamino)-5-nitropyrimidine 
• 2273-93-0 2,6-dichloro-7-methylpurine 

Downstream Products

• 1273307-62-2 2-(2-methoxyethyl)-9-methyl-7-({3-[4-(trifluoromethyl)phenyl]azetidin-1-yl}carbonyl)-7,9-dihydro-8H-purine-8-one hydrochloric acid salt 
• 1273388-39-8 2-(3-methoxypropyl)-9-methyl-7-({3-[4-(trifluoromethyl)phenyl]azetidin-1-yl}carbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273315-11-9 2-chloro-9-methyl-7H-purin-8(9H)-one 
• 1273315-68-6 2-cyclohexyl-9-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7,9-dihydro-8H-purine-8-one 
• 1273315-70-0 2-cyclohexyl-9-methyl-7,9-dihydro-8H-purine-8-one 
• 1273315-37-9 9-methyl-2-(2-phenylethyl)-7,9-dihydro-8H-purine-8-one 
• 1273315-21-1 9-methyl-2-[(E)-2-phenylethenyl]-7,9-dihydro-8H-purine-8-one 
• 1273304-67-8 2-benzyl-9-methyl-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273302-07-0 2-(2-fluorophenyl)-9-methyl-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273298-36-4 9-methyl-2-[(E)-2-phenylethenyl]-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 872856-32-1 N-[4-methyl-3-(2-chloro-8-methyl-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-trifluoromethyl-benzamide 

Relevant academic research and scientific papers

FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

Substituted purine derivative and preparation method and application thereof

The invention discloses a substituted purine derivative with the structure as shown in a general formula I and a preparation method and application of the derivative. The invention further provides N-oxide or a stereisomer form or a stereisomer mixture or pharmaceutically acceptable salts of the substituted purine derivative. The invention further provides the preparation method of the substituted purine derivative and the application of a composition containing one or more compounds in preparing drugs for resisting hepatitis B. Please see the formula in the description.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

8-OXODIHYDROPURINE DERIVATIVE

The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di